Vancouver, Canada, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended October 31, 2025, with the U.S. Securities and Exchange Commission (the 'SEC'). The report is available on the SEC's we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Jurisdicti ...

Core Insights - Clearmind Medicine Inc. has successfully completed treatment for all patients in the second cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, an oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][2][3] Group 1: Clinical Trial Progress - The second cohort included six patients from leading clinical sites such as Johns Hopkins University and Tel Aviv Sourasky Medical Center, completing treatment as per protocol [2] - This milestone follows positive results from the first cohort, which indicated a favorable safety profile and preliminary efficacy, including reduced cravings and withdrawal symptoms [2][3] - The CEO of Clearmind Medicine expressed satisfaction with the progress and highlighted the strong interest in CMND-100 as a potential innovative therapy for AUD, a condition with significant unmet medical needs [3] Group 2: Company Overview - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address widespread health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] - Clearmind's shares are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under "CWY0" [5]

Core Viewpoint - Clearmind Medicine Inc. has regained compliance with Nasdaq's minimum bid price requirement after its shares closed at $1.00 or greater for 10 consecutive business days, resolving a previous non-compliance issue [1][3]. Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics aimed at addressing significant under-treated health issues, including alcohol use disorder [4]. - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [5]. Compliance Update - On December 4, 2025, Nasdaq notified the company of its non-compliance with the minimum bid price requirement due to its shares trading below $1.00 for over 30 consecutive business days [2]. - Following a period of compliance, Nasdaq confirmed on December 30, 2025, that the company's shares had met the minimum bid price requirement, thus closing the matter [3].

Core Insights - Clearmind Medicine Inc. has made significant progress in 2025, particularly in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD) [1][2] Clinical Trial Progress - Clearmind advanced its multinational Phase I/IIa clinical trial for CMND-100, with site activations at prestigious institutions such as Yale School of Medicine and Johns Hopkins University [3] - The company successfully initiated first-in-human dosing, completed treatment and enrollment for the first cohort, and reported positive top-line safety and tolerability results with no serious adverse events [3] - Enrollment and dosing for the second cohort were completed, accelerating the path toward further data readouts [3] Independent Safety Endorsement - Clearmind received unanimous approval from the Data and Safety Monitoring Board (DSMB) to continue the Phase I/IIa clinical trial following an interim review, reinforcing CMND-100's favorable safety profile [4] Global Footprint Expansion - The company strengthened its intellectual property portfolio with multiple international patent filings and publications targeting various indications, including weight loss, obesity, and mental health disorders [5] Leadership Commentary - The CEO of Clearmind highlighted 2025 as a pivotal year for the company, emphasizing its transition into a clinical-stage entity and commitment to delivering transformative treatments for addictions and mental health challenges [6] Intellectual Property Portfolio - Clearmind's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [8]

Core Insights - Clearmind Medicine Inc. has made significant progress in 2025, particularly in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD) [1][2] Clinical Trial Progress - Clearmind advanced its multinational Phase I/IIa clinical trial for CMND-100, with site activations at prestigious institutions such as Yale School of Medicine and Johns Hopkins University [3] - The company successfully initiated first-in-human dosing, completed treatment and enrollment for the first cohort, and reported positive top-line safety and tolerability results with no serious adverse events [3] - Enrollment and dosing for the second cohort were completed, accelerating the path toward further data readouts [3] Independent Safety Endorsement - Clearmind received unanimous approval from the Data and Safety Monitoring Board (DSMB) to continue the Phase I/IIa clinical trial following an interim review, reinforcing CMND-100's favorable safety profile [4] Global Footprint Expansion - The company strengthened its intellectual property portfolio with multiple international patent filings and publications targeting various health indications, including weight loss, obesity, and mental health disorders [5] Leadership Commentary - The CEO of Clearmind highlighted 2025 as a pivotal year for the company, emphasizing its transition into a clinical-stage entity and commitment to delivering transformative treatments for addictions and mental health challenges [6] Intellectual Property Portfolio - Clearmind's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [8]

Core Insights - Clearmind Medicine Inc. has successfully completed patient enrollment for the second cohort in its FDA-approved Phase I/IIa clinical trial for CMND-100, an oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][4] - The first cohort showed promising safety and efficacy results, indicating a favorable safety profile and preliminary signs of reduced cravings and withdrawal symptoms [2][4] - The rapid enrollment of the second cohort underscores the commitment of collaborating clinical centers to advance innovative treatments for AUD, a condition with limited effective options affecting millions globally [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [1][5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property [6] Clinical Trial Details - The multinational Phase I/IIa trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, with dosing for the second cohort expected to start soon [4]

Core Viewpoint - Clearmind Medicine Inc. is implementing a reverse stock split to comply with Nasdaq regulations, which will significantly reduce its outstanding shares while maintaining authorized share capital [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will occur at a ratio of 40 for 1 on December 15, 2025, reducing outstanding shares from approximately 60 million to 1.5 million [1][2]. - The board of directors approved this decision on November 12, 2025, and no fractional shares will be issued; instead, they will be rounded up to the nearest whole share [2]. Group 2: Stock Performance - Following the announcement, CMND's share price dropped 29.92% in after-hours trading, with the stock closing at $0.11 before the announcement, reflecting a decrease of 6.08% [3]. - The current stock price is $2.61, indicating a decrease of approximately 12.14% [3]. - The stock has shown significant volatility, trading between $2.54 and $3.25 on the day of the announcement, with a yearly high of $87.20 and a low of $2.54 [4]. Group 3: Market Capitalization and Trading Volume - CMND's market capitalization is approximately $14.27 million, with a trading volume of 247,625 shares [4].

Core Insights - Clearmind Medicine Inc. has published a review article validating the therapeutic potential of its candidate MEAI in treating alcohol use disorder (AUD) [1][2] - The review highlights MEAI's advantages over classical psychedelics, including a milder subjective experience and lower abuse potential [2] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health issues, particularly AUD [4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents [5] Therapeutic Effects of MEAI - Recreational users typically take MEAI in doses of 1 to 2 mg/kg, reporting positive effects such as reduced desire to consume alcohol within 4 hours [6] - MEAI's receptor interaction profile suggests it may stimulate serotonin release while having a lower risk of abuse compared to other substances like MDMA [6] Adverse Effects - Users of MEAI have not reported serious adverse events, and it is expected to have milder toxicity compared to MDMA due to its receptor interactions [6]

Core Points - Clearmind Medicine Inc. has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000, as confirmed by a notification letter from Nasdaq on December 10, 2025 [1][2] - The company is under continued monitoring by Nasdaq for compliance with the Minimum Stockholders' Equity Rule, with potential delisting if compliance is not demonstrated in the next periodic report [2] - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [3] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as needed [4]